The ambiguous role of FPR1 in immunity and inflammation

by Erika Vacchelli, Julie Le Naour, Guido Kroemer
Published 2020-01-01

FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin

by Jonathan G. Pol, Julie Le Naour, Guido Kroemer
Published 2020-01-01

Trial watch: STING agonists in cancer therapy

by Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli, Guido Kroemer
Published 2020-01-01

Trial watch: TLR3 agonists in cancer therapy

by Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli
Published 2020-01-01

Trial watch: IDO inhibitors in cancer therapy

by Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli
Published 2020-01-01

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

by Giorgio Frega, Qi Wu, Julie Le Naour, Erika Vacchelli, Lorenzo Galluzzi, Guido Kroemer, Oliver Kepp
Published 2020-01-01

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1

by Zsofia Sztupinszki, Julie Le Naour, Erika Vacchelli, Pierre Laurent-Puig, Suzette Delaloge, Zoltan Szallasi, Guido Kroemer
Published 2021-01-01

No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19

by Adriana Petrazzuolo, Julie Le Naour, Erika Vacchelli, Pascale Gaussem, Syrine Ellouze, Georges Jourdi, Eric Solary, Michaela Fontenay, David M. Smadja, Guido Kroemer
Published 2020-01-01

A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice

by Sarah Lévesque, Julie Le Naour, Federico Pietrocola, Juliette Paillet, Margerie Kremer, Francesca Castoldi, Elisa E. Baracco, Yan Wang, Erika Vacchelli, Gautier Stoll, Ariane Jolly, Pierre De La Grange, Laurence Zitvogel, Guido Kroemer, Jonathan G. Pol
Published 2019-11-01